WASHINGTON, Sept. 16 /PRNewswire-USNewswire/ -- Antidepressant drug Paxil, which generated about 2.1% of GlaxoSmithKline's total revenue last year, has been known to cause birth defects, but the world's second-biggest drugmaker hid its risks to pump up profits, a Philadelphia court has heard.
According to available information, Glaxo failed to properly test the drug and urged scientists to conceal Paxil's risks. The Philadelphia trial is the first of more than 600 cases against the London-based company.
Are you satisfied with the way your regular news sources report on these important stories? If not, try Pharmaceutical Industry Today (http://pharmaceuticals.einnews.com/), for free, to see what you may have been missing.
-- GlaxoSmithKline News - http://pharmaceuticals.einnews.com/news/glaxosmithkline
-- Paxil News - http://pharmaceuticals.einnews.com/news/paxil
-- Latest Pharmaceutical News - http://pharmaceuticals.einnews.com/
For a free trial to Pharmaceutical Industry Today, go to: http://pharmaceuticals.einnews.com/users/register.php
About the publisher of Pharmaceutical Industry Today, EIN News, http://www.einnews.com/
EIN News was established in 1995, and through the years has built more than 200,000 news feeds organized within over 80 individual news sites. The company has launched the well-known 'Russia News Service' brand and opened Internet news access to China with 'Inside China Today'.
Offering a unique combination of human editing and proprietary scanning software, EIN News won Europe's coveted Momentum Award as the most innovative internet company on the continent. Serving millions of customers, the company distributes its feeds via email or mobile news alerts, online and other channels such as Newsfeed Maker (http://www.newsfeedmaker.com/) and EIN Presswire (http://www.einpresswire.com/).
|SOURCE EIN News|
Copyright©2009 PR Newswire.
All rights reserved